Viewing nowCombinationEmpagliflozin and Linagliptin Tablet 10/5 mg (Empagliflozin, Linagliptin (Unmodified))
Empagliflozin 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.

MFDS item code 202502441 · Approved 2025.09.15 · Insurance code 646005860
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication contains two components, empagliflozin and linagliptin, which work together to help patients with type 2 diabetes control their blood sugar levels. It is used in conjunction with dietary and exercise therapies to effectively manage blood sugar levels. Patients may achieve more stable blood sugar control through this medication. Continuous use and improvements in lifestyle can enhance therapeutic effects. This medication improves the blood sugar control of patients with type 2 diabetes.
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If empagliflozin 10 mg/linagliptin 5 mg is tolerated and additional glycemic control is needed, the dose may be increased to 25/5 mg once daily. Patients switching to this medicine from concomitant therapy with empagliflozin and linagliptin should receive the doses they were previously taking. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Patients with renal impairment This medicine is not recommended for patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 for the purpose of improving glycemic control. No dose adjustment is required in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Older adults No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older.
This medication consists of two active ingredients, empagliflozin and linagliptin, and is used in the treatment of diabetes. Firstly, this medication should not be administered to certain patients. For example, individuals with allergic reactions to any components of this medication or other constituents, patients with type 1 diabetes or diabetic ketoacidosis, and those undergoing dialysis should not take this medication. Patients with impaired kidney function, heart failure, or a history of pancreatitis need to exercise special caution when taking this medication. If pancreatitis is suspected, the medication should be stopped immediately, and symptoms of pancreatitis include persistent severe abdominal pain. Additionally, a skin condition known as bullous pemphigoid may occur during the use of this medication, so if any blisters or erosion appear on the skin, immediate consultation with a physician is necessary. The most common side effect of this medication is urinary tract infections, which may occur more frequently in women. Genital fungal infections may also occur, so caution is advised. Symptoms of hypoglycemia are rare with this medication alone, but the risk of hypoglycemia may increase when taken in conjunction with other diabetes medications such as insulin or sulfonylureas, so blood sugar management should be closely monitored. This medication may lower blood pressure, so patients with hypotension or cardiovascular diseases need to be careful, and it is advised to consult a physician in situations where dehydration or fluid loss is a concern. It is recommended that women who are pregnant or breastfeeding avoid taking this medication, and its safety and efficacy have not been established in children under 18 years of age, hence it should not be used in this population. During the use of this medication, caution is advised while driving or operating machinery, especially if there is a risk of hypoglycemia. Finally, this medication may interact with other drugs, so if taking medications such as insulin, sulfonylureas, diuretics, or lithium, it is essential to consult a physician or pharmacist. If any abnormal symptoms occur while taking this medication, it is important to consult healthcare professionals immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.
Yellow film-coated tablet with a round, biconvex shape
Box - 30 tablets/box [10 tablets/PTP x 3], Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationLinagliptin Micronized 5mg · Empagliflozin 25mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Green Cross
CombinationLinagliptin Micronized 5mg · Empagliflozin 10mg
Tablet · Prescription medication · Combination
Green Cross Corporation
CombinationEmpagliflozin 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Empagliflozin 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Cheil Pharmaceutical Co., Ltd.
Empagliflozin 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.